Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of synthetic method of anseltrapib chiral intermediate

A synthetic method, the technology of anseltrapib, which is applied in the field of medicine, achieves the effects of mild reaction conditions, improved yield and purity, and high selectivity

Active Publication Date: 2020-03-17
LUNAN PHARMA GROUP CORPORATION
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] The technical problem to be solved by the present invention is to avoid the use of ruthenium metal complex catalysts and provide a cheap and easy-to-obtain catalyst. The preparation method of the present invention has high catalytic selectivity, mild reaction conditions, single product, and the obtained anseltrapib intermediate High optical purity and high yield, low production cost, environmentally friendly, more suitable for industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of synthetic method of anseltrapib chiral intermediate
  • A kind of synthetic method of anseltrapib chiral intermediate
  • A kind of synthetic method of anseltrapib chiral intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Preparation of (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-2-Boc-amino-propanol

[0034] Under the protection of argon, add 300ml of petroleum ether to the reaction bottle, cool down to -5~0℃, add 3ml (0.01mol) of (R)-2-methyl-CBS-oxazoborane, borane dimethyl sulfide Complex 15ml (0.25mol), stirring for 30min; control 5 ~ 10 ℃ dropwise containing the petroleum ether solution containing 65g (0.162mol) of the compound of formula (Ⅲ); after dropping, stir and react for 1h at 5 ~ 10 ℃, the reaction is complete; cool down To -5 ~ 0 ℃, add methanol dropwise, stir for 30min, add 1mol / L sulfuric acid, stir for 30min. Stand to separate and collect the organic phase; the organic phase is washed once with 1mol / L sulfuric acid, 5% sodium bicarbonate solution and purified water respectively, the obtained organic phase is dried by adding anhydrous sodium sulfate, filtered, and the filtrate is concentrated to dryness under reduced pressure 62.3 g of the crude product was obtained, and...

Embodiment 2

[0036] Preparation of (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-2-Boc-amino-propanol

[0037] Under the protection of argon, add 300ml of acetone to the reaction bottle, cool down to -5~0℃, add 6ml (0.02mol) of (R)-2-methyl-CBS-oxazoborane, borane dimethyl sulfide complex Compound 30ml (0.5mol), stirring for 30min; control 5 ~ 10 ℃ dropwise acetone solution containing 65g (0.162mol) of compound of formula (Ⅲ); after dropping, stir and react for 1h at 5 ~ 10 ℃, the reaction is complete; cool down to - 5~0℃, add ethanol dropwise, stir for 30min, add 1mol / L hydrochloric acid, stir for 30min. Stand for stratification, collect the organic phase; wash the organic phase with 1mol / L hydrochloric acid, 5% sodium bicarbonate solution and purified water successively, add anhydrous sodium sulfate to the obtained organic phase, dry, filter, and concentrate the filtrate to dryness under reduced pressure 63.2 g of the crude product was obtained, and the (R, S) / (R, R) configuration ratio de...

Embodiment 3

[0039] Preparation of (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-2-Boc-amino-propanol

[0040] Under the protection of argon, add 300ml of chloroform into the reaction flask, cool down to -5~0℃, add 10ml (0.034mol) of (R)-2-methyl-CBS-oxazoborane, borane dimethyl sulfide Ether complex 30ml (0.5mol), stirred for 30min; controlled 5 ~ 10 ℃, dropwise added chloroform solution containing 65g (0.162mol) of the compound of formula (Ⅲ); after dropping, stirred and reacted for 1h at 5 ~ 10 ℃, the reaction was complete ; Cool down to -5~0°C, add methanol dropwise, stir for 30 minutes, add 1mol / L sulfuric acid, and stir for 30 minutes. Stand to separate and collect the organic phase; the organic phase was washed once with 1mol / L sulfuric acid, 5% sodium bicarbonate solution and purified water respectively, the obtained organic phase was dried by adding anhydrous magnesium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure 63.5 g of the crude product ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for synthesizing an anacetrapib intermediate (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-2-Boc-amino-propanol. The method comprises: adding (R)-2-methyl-CBS-oxazaborolidine and a borane-dimethyl sulfide complex to 1-(3,5-bis(trifluoromethyl)phenyl)-2-Boc-amino-acetone in a certain solvent at a certain temperature, and carrying out a reducing reaction. According to the present invention, the chiral catalytic reaction does not use the expensive metallic ruthenium catalyst, the catalytic selectivity is high, the reaction condition is mild, the product is single, the obtained intermediate has the high optical purity and the high yield, the production cost is low, and the method is environment is environmentally friendly, and is suitable for Industrial production.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a method for synthesizing a chiral intermediate of anseltrapib. Background technique [0002] Cardiovascular and cerebrovascular diseases have become one of the main causes of death in developed countries and my country's urban and rural population, and atherosclerosis is the main pathological basis of cardiovascular and cerebrovascular diseases. Systematic etiology studies have shown that atherosclerosis is a pathological development process. The main pathogenic factors are hyperlipidemia and lipoprotein metabolism disorders. Cholesterol ester transfer protein (CETP) promotes lipid exchange and transport between plasma lipoproteins in plasma. The result of high expression of CETP is that the amount of cholesterol ester of high-density lipoprotein (HDL-C) decreases, and the amount of cholesterol ester of very low-density lipoprotein and low-density lipoprotein (VLDL-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C269/06C07C269/08C07C271/16C07B53/00B01J31/22
CPCB01J31/226B01J2231/643C07B53/00C07B2200/07C07C269/06C07C269/08C07C271/16
Inventor 张贵民臧超许建国夏明军
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com